Literature DB >> 22460595

Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice.

Naglaa El-Lakkany1, Sayed Hassan Seif El-Din, Lamia Heikal.   

Abstract

One of the problems of praziquantel (PZQ) is its very low aqueous solubility. Moreover, its dissolution rate is considered the limiting factor for its bioavailability. This work correlates the physical properties and the dissolution behavior of PZQ-polyvinylpyrrolidone (PVP) solid dispersion (SD) at the ratios of 1:1 and 3:7 with its oral bioavailability and its in vivo efficacy against Schistosoma mansoni (S. mansoni). The PZQ and PZQ-PVP SD were characterized by infrared spectroscopy, differential scanning calorimetry, scanning electron microscopy (SEM) and solubility test. Results showed a decrease in crystallinity, possible interaction between PZQ and PVP, greater increase in dissolution rate and appreciable reduction in particle size. S. mansoni-infected mice treated orally with either pure PZQ or PZQ-PVP at a single dose of 500 mg/kg showed a higher increase in AUC((0-8h)), C (max), K(a) and t (1/2e) with a significant decrease in k (el) versus the corresponding uninfected mice. Moreover, uninfected and infected mice treated with PZQ-PVP SD showed 2.3-, 1.6- and 1.3-, 1.25-fold increase, respectively, in AUC((0-8h)) and C(max), with a decrease in k(el) and increase in t (1/2e) by twofold versus the corresponding pure PZQ-treated groups. Percentage worm reduction at all administered doses (62.5, 125, 250, 500 and 1,000 mg/kg) was significantly higher (1- to 1.5-fold) in mice treated with PZQ-PVP SD (ED₅₀ = 40.92) versus those treated with pure PZQ (ED₅₀ = 99.29). In addition, a significant reduction in total tissue egg load concomitant with a significant decrease in total immature and mature eggs and an increase in dead eggs in PZQ-PVP SD-treated groups versus their corresponding pure PZQ-treated groups was recorded. Solid dispersion of PZQ with PVP could lead to a further improvement in the effectiveness of PZQ therapy especially with the appearance of some PZQ-tolerant S. mansoni isolates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460595     DOI: 10.1007/s13318-012-0089-6

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  44 in total

Review 1.  Drugs for the control of parasitic diseases: current status and development in schistosomiasis.

Authors:  Alan Fenwick; Lorenzo Savioli; Dirk Engels; N Robert Bergquist; Matthew H Todd
Journal:  Trends Parasitol       Date:  2003-11

2.  Dissolution rates of high energy sulfathiazole--povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies.

Authors:  A P Simonelli; S C Mehta; W I Higuchi
Journal:  J Pharm Sci       Date:  1976-03       Impact factor: 3.534

3.  Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues.

Authors:  A W Cheever
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

4.  Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions.

Authors:  M Franco; G Trapani; A Latrofa; C Tullio; M R Provenzano; M Serra; M Muggironi; G Biggio; G Liso
Journal:  Int J Pharm       Date:  2001-08-28       Impact factor: 5.875

5.  Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel.

Authors:  S William; A Sabra; F Ramzy; M Mousa; Z Demerdash; J L Bennett; T A Day; S Botros
Journal:  Int J Parasitol       Date:  2001-08       Impact factor: 3.981

6.  Dissolution rate of furosemide from polyethylene glycol solid dispersions.

Authors:  N Ozdemir; S Ordu
Journal:  Farmaco       Date:  1997-10

7.  Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method.

Authors:  Susumu Hasegawa; Takeshi Hamaura; Naho Furuyama; Akira Kusai; Etsuo Yonemochi; Katsuhide Terada
Journal:  Int J Pharm       Date:  2005-09-30       Impact factor: 5.875

8.  Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties.

Authors:  O I Corrigan; E M Holohan
Journal:  J Pharm Pharmacol       Date:  1984-04       Impact factor: 3.765

9.  Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Lars L Gustafsson; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

10.  Different levels of Schistosoma mansoni infection induce changes in drug-metabolizing enzymes.

Authors:  S A Sheweita; S A Mangoura; A G el-Shemi
Journal:  J Helminthol       Date:  1998-03       Impact factor: 2.170

View more
  3 in total

1.  Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.

Authors:  Gina S El-Feky; Wael S Mohamed; Hanaa E Nasr; Naglaa M El-Lakkany; Sayed H Seif El-Din; Sanaa S Botros
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

2.  Niosomal versus nano-crystalline ivermectin against different stages of Trichinella spiralis infection in mice.

Authors:  Dalia A Elmehy; Marwa A Hasby Saad; Gamal M El Maghraby; Mona F Arafa; Nema A Soliman; Heba H Elkaliny; Dina I Elgendy
Journal:  Parasitol Res       Date:  2021-05-04       Impact factor: 2.289

3.  Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel.

Authors:  Eglal I Amer; Iman Fathy Abou-El-Naga; Laila M Boulos; Heba S Ramadan; Salwa S Younis
Journal:  Biomedica       Date:  2022-03-01       Impact factor: 1.173

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.